Inhibition of CD40L-induced production of VEGF and cytokines (IL-6) and activation of signaling pathways, proliferation, and survival of CLL [44] and MM [42] cells is caused by lucatumumab (HCD122). Here, IL6 is linked to Miyoshi myopathy.